The full analysis has yet to be completed, but initial findings from the breast cancer study appear positive as researchers begin enrolling for a third trial.
The team used CRISPR to inactivate a gene in colon organoids, and found that a specific DNA repair defect underlies a mutational signature in some cancers.
Swedish Cancer Institute has enlisted machine-learning technology vendor GNS Healthcare to model patient-specific breast cancer tumor data.
Researchers saw mismatch repair-related mutations in a significant subset of breast cancers, hinting at potential response to checkpoint blockade immunotherapy.
Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.
Mutations in other genes like PALB2 also confer breast cancer risk, the Philadelphia Inquirer writes.
In PLOS this week: gene classifier for predicting breast cancer metastases, call for standardized Zika virus reference sequences, and more.
The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The company said that more than 95 percent of eligible early-stage breast cancer patients can now have the test paid by insurance.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.